Lisa Schlagereditorial@labpulse.comGuidelineIs the new Medicare NGS payment policy really a win for patients?The implications of the new policy, however, are less positive than what appears at the surface. Patients seeking germline testing are only slightly better off now than they were two years ago, before the NCD was initiated.February 4, 2020Page 1 of 1Top StoriesCancerInvivoscribe, Complete Genomics partner to develop NGS tests for cancer research, detectionUnder the terms of the deal, Invivoscribe will be responsible for the development of biomarker tests, including test controls and associated bioinformatics software. The tests will run on Complete Genomics' NGS platforms.Regulatory ApprovalSeegene obtains IVDR certification for 30 diagnostic assaysPolicy and RegulationAdvocacy groups in letter urge FDA to develop regulations for lab-developed testsCollaborationNucleai, Adlai Nortye collaborate on biomarkers for clinical trialsSponsor ContentVisit our Molecular Diagnostics Community